Get started
Author

Shankaranarayana Paneesha

Observed names: S Paneesha, S. PANEESHA, S. Paneesha
OpenAlex ID: A5002161189
Frequency, demographics and risk (according to tumour type or site) of cancer-associated thrombosis among patients seen at outpatient DVT clinics
2009 · Shankaranarayana Paneesha, Aidan McManus, et al. · Thrombosis and Haemostasis · 99
Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism
2010 · L Knowlson, S Bacchu, et al. · Journal of Clinical Pathology · 72
Peripheral blood stem cell transplantation for POEMS syndrome
2002 · KS Peggs, S Paneesha, et al. · Bone Marrow Transplantation · 58
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
2025 · Lorenzo Falchi, Marcel Nijland, et al. · The Lancet · 41
High D ‐dimer levels at presentation in patients with venous thromboembolism is a marker of adverse clinical outcomes
2006 · S. Paneesha, E. Cheyne, et al. · British Journal of Haematology · 25
PDF
The P2X7 receptor gene polymorphism 1513 A→C has no effect on clinical prognostic markers and survival in multiple myeloma
2005 · Shankaranarayana Paneesha, Jane Starczynski, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 21
The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia
2006 · N. C. Pemberton, S. Paneesha, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 20
Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial
2024 · Lise J Estcourt, Zoe K McQuilten, et al. · The Lancet Haematology · 15
Time Limited Exposure to a ROR1 Targeting Bispecific T Cell Engager (NVG-111) Leads to Durable Responses in Subjects with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
2023 · William Townsend, Sarah Leong, et al. · Blood · 15
Burkitt's lymphoma: single-centre experience with modified BFM protocol
2002 · E. HARRIS, S. PANEESHA, et al. · Clinical & Laboratory Haematology · 14
Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study
2023 · Peter Hillmen, David Allan Cairns, et al. · Blood · 11
Successful treatment of a patient with chronic lymphocytic leukaemia (CLL) presenting with bony metastases with aggressive antibody and chemotherapy
2005 · H. NARAYAN, D. BANDYOPADHYAY, et al. · Clinical & Laboratory Haematology · 10
Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial
2016 · Elizabeth H Phillips, Amy A Kirkwood, et al. · Blood · 9
S145: the Combination of Ibrutinib Plus Venetoclax Results in a High Rate of Mrd Negativity in Previously Untreated Cll: the Results of the Planned Interim Analysis of the Phase Iii Ncri Flair Trial
2022 · P. Hillmen, A. Pitchford, et al. · HemaSphere · 7
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial
2019 · Andrea Kühnl, Clare Peckitt, et al. · Annals of Hematology · 7
High D-dimer level at presentation in patients with venous thrombosis is a marker for malignancy.
2005 · S Paneesha, E Cheyne, et al. · PubMed · 6
Successful pregnancy in a case of congenital thrombotic thrombocytopenic purpura
2010 · S. Meti, S. Paneesha, et al. · Journal of Obstetrics and Gynaecology · 5
More on thromboprophylaxis: Quantifying risk for venous thromboembolism
2009 · Shankaranarayana Paneesha, Aidan McManus, et al. · Thrombosis and Haemostasis · 5
Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial
2013 · Andrew McMillan, Kirit M Ardeshna, et al. · Blood · 4
Impact of venous thromboembolism on survival in patients with malignancy
2009 · Shankaranarayana Paneesha, Anand Lokare, et al. · British Journal of Haematology · 4
PDF
Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
2024 · Andrea Kuhnl, Amy A Kirkwood, et al. · Blood · 2
PDF
A Retrospective Single Center Comparison of Cyclophosphamide Plus G-CSF Versus G-CSF Alone for Peripheral Blood Stem Cell (PBSC) Mobilisation Following First Line Therapy in Patients with Multiple Myeloma
2015 · Richard S Whitmill, David J Lewis, et al. · Blood · 2
Pre-Transplantation Assessment Of Mortality (PAM) Score Is a Poor Predictor For Survival In The Highest Risk Group When Used In T Cell Depleted Myeloablative Allogeneic Transplants
2013 · Bhuvan Kishore, Daniel Wiseman, et al. · Blood · 2
Treatment outcomes using involved field and involved site radiotherapy for NHL and HL : Retrospective analysis from a large UK Radiotherapy centre
2017 · D.M. Jayalathike, A. Stevens, et al. · Hematological Oncology · 1
PDF
Colony Stimulating Factors (Pegfilgrastim or Lenograstim) Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay with No Impact on Progression Free Survival (PFS) or Overall Survival (OS)
2015 · Georgina Mayer, Bhuvan Kishore, et al. · Blood · 1
Works count: 54
Citation count: 460
H-index: 11
I10-index: 12
Year
Topic
Type